文献速递呼吸道感染呼吸危重症与机械通气

高剂量吸入一氧化氮治疗COVID-19急性低氧性呼吸衰竭:多中心II期试验

High-Dose Inhaled Nitric Oxide in Acute Hypoxemic Respiratory Failure Due to COVID-19: A Multicenter Phase II Trial.
PubMed 文献 · Am J Respir Crit Care Med · 2023-01-01

本研究为多中心、单盲、随机对照平行组II期试验,纳入193例机械通气COVID-19肺炎成人患者,比较吸入80 ppm一氧化氮48小时与常规治疗。结果显示干预组48小时PaO2/FiO2平均变化为28.3 mmHg,对照组为21.4 mmHg,组间平均差39.1 mmHg(95% CrI 18.1至60.3)。28天时达到PaO2/FiO2>300 mmHg的比例干预组27.7%,对照组17.2%(RR 2.03,95% CrI 1.11至3.86),通气时长及28天、90天死亡率无差异,未报告严重不良事件。

要点

  • 高剂量吸入一氧化氮可改善COVID-19急性低氧性呼吸衰竭患者48小时氧合。
  • 28天时达到PaO2/FiO2>300 mmHg的比例干预组更高(27.7% vs 17.2%)。
  • 通气时长及28天、90天死亡率无差异,未报告严重不良事件。

核心结论

  • 高剂量吸入一氧化氮可改善COVID-19急性低氧性呼吸衰竭成人患者48小时PaO2/FiO2,优于常规治疗。

研究设计与样本

  • 多中心、单盲、随机对照平行组II期试验,纳入193例机械通气COVID-19肺炎成人患者,干预组吸入80 ppm一氧化氮48小时,对照组接受常规治疗(无安慰剂)。

主要发现

  • 48小时PaO2/FiO2平均变化干预组28.3 mmHg,对照组21.4 mmHg,平均差39.1 mmHg(95% CrI 18.1至60.3)。
  • 达到PaO2/FiO2>300 mmHg的平均时间干预组8.7天,对照组8.4天,平均差0.44(95% CrI 23.63至4.53)。
  • 28天达到PaO2/FiO2>300 mmHg的比例干预组27.7%,对照组17.2%,风险比2.03(95% CrI 1.11至3.86)。
  • 通气时长及28天、90天死亡率无差异,未报告严重不良事件。

临床怎么用

  • 对COVID-19急性低氧性呼吸衰竭的机械通气成人患者,可考虑使用高剂量吸入一氧化氮以改善48小时氧合,但需注意其对通气时长和死亡率无获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: The effects of high-dose inhaled nitric oxide on hypoxemia in coronavirus disease (COVID-19) acute respiratory failure are unknown. Objectives: The primary outcome was the change in arterial oxygenation (PaO2/FiO2) at 48 hours. The secondary outcomes included: time to reach a PaO2/FiO2.300mmHg for at least 24 hours, the proportion of participants with a PaO2/FiO2.300mmHg at 28 days, and survival at 28 and at 90 days. Methods: Mechanically ventilated adults with COVID-19 pneumonia were enrolled in a phase II, multicenter, single-blind, randomized controlled parallel-arm trial. Participants in the intervention arm received inhaled nitric oxide at 80 ppm for 48 hours, compared with the control group receiving usual care (without placebo). Measurements and Main Results: A total of 193 participants were included in the modified intention-to-treat analysis. The mean change in PaO2/FiO2 ratio at 48 hours was 28.3mmHg in the intervention group and 21.4mmHg in the control group (mean difference, 39.1mmHg; 95% credible interval [CrI], 18.1 to 60.3). The mean time to reach a PaO2/FiO2.300mmHg in the interventional group was 8.7 days, compared with 8.4 days for the control group (mean difference, 0.44; 95% CrI, 23.63 to 4.53). At 28 days, the proportion of participants attaining a PaO2/FiO2.300mmHg was 27.7% in the inhaled nitric oxide group and 17.2% in the control subjects (risk ratio, 2.03; 95% CrI, 1.11 to 3.86). Duration of ventilation and mortality at 28 and 90 days did not differ. No serious adverse events were reported. Conclusions: The use of high-dose inhaled nitric oxide resulted in an improvement of PaO2/FiO2 at 48 hours compared with usual care in adults with acute hypoxemic respiratory failure due to COVID-19.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Di Fenza R, Shetty NS, Gianni S, et al. High-Dose Inhaled Nitric Oxide in Acute Hypoxemic Respiratory Failure Due to COVID-19: A Multicenter Phase II Trial. Am J Respir Crit Care Med. 2023. PMID: 37774011. doi:10.1164/rccm.202304-0637OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。